Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
- PMID: 18390575
- DOI: 10.1136/gut.2007.146019
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
Abstract
Background: Clinical predictors of advanced non-alcoholic liver disease (NAFLD) are needed to guide diagnostic evaluation and treatment.
Methods: To better understand the demographics of NAFLD and risk factors for advanced disease, this study analysed 827 patients with NAFLD at two geographically separate tertiary medical centres.
Results: The cohort was 51% female and had a median body mass index (BMI) of 33 kg/m(2); 3% had a normal BMI. Common co-morbidities included hypertension (60%) and diabetes (35%); insulin resistance was present in 91% and advanced fibrosis in 24% of patients. When comparing patients with no fibrosis or mild fibrosis to those with advanced fibrosis, BMI > or = 28 kg/m(2), age > 50 years, and aspartate transaminase/alanine aminotransferase (AST/ALT) ratio > or = 0.8, a quantitative assessment check index (QUICKI) score < 0.294 (equivalent to homeostasis model assessment (HOMA) > 6.2) and the presence of diabetes mellitus (DM) were individually associated by univariate analysis with odds ratios (ORs) of > or = 2.4 for advanced fibrosis. Based on the results of forced entry logistic regression analysis, three variables were combined in a weighted sum (BMI > or = 28 = 1 point, AAR of > or = 0.8 = 2 points, DM = 1 point) to form an easily calculated composite score for predicting advanced fibrosis called the BARD score. A score of 2-4 was associated with an OR for advanced fibrosis of 17 (confidence interval 9.2 to 31.9) and a negative predictive value of 96%.
Conclusions: Insulin resistance and its co-morbidities are often present in patients with NAFLD. An easily calculated score based on readily available clinical data can reliably exclude the presence of advanced fibrosis in these patients, particularly among non-diabetics.
Comment in
-
Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)?Gut. 2008 Oct;57(10):1351-3. doi: 10.1136/gut.2008.154435. Gut. 2008. PMID: 18791116 No abstract available.
-
Applicability of BARD score to Japanese patients with NAFLD.Gut. 2009 Nov;58(11):1566-7; author reply 1567. doi: 10.1136/gut.2009.182758. Gut. 2009. PMID: 19834122 No abstract available.
Similar articles
-
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077. Gut. 2010. PMID: 20801772
-
Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.J Clin Gastroenterol. 2009 Sep;43(8):765-72. doi: 10.1097/MCG.0b013e31819e9048. J Clin Gastroenterol. 2009. PMID: 19525862
-
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.Obes Surg. 2005 Mar;15(3):310-5. doi: 10.1381/0960892053576820. Obes Surg. 2005. PMID: 15826462
-
The epidemiology of nonalcoholic fatty liver disease in adults.J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. doi: 10.1097/01.mcg.0000168638.84840.ff. J Clin Gastroenterol. 2006. PMID: 16540768 Review.
-
How should we manage patients with non-alcoholic fatty liver disease in 2007?J Gastroenterol Hepatol. 2007 Jun;22(6):801-8. doi: 10.1111/j.1440-1746.2007.04977.x. J Gastroenterol Hepatol. 2007. PMID: 17565632 Review.
Cited by
-
Identifying High-Risk NASH Patients: What We Know so Far.Hepat Med. 2020 Aug 21;12:125-138. doi: 10.2147/HMER.S265473. eCollection 2020. Hepat Med. 2020. PMID: 32982495 Free PMC article. Review.
-
Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease.JHEP Rep. 2020 Jun 15;2(5):100137. doi: 10.1016/j.jhepr.2020.100137. eCollection 2020 Oct. JHEP Rep. 2020. PMID: 32775974 Free PMC article.
-
Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy.J Clin Med. 2022 Mar 22;11(7):1756. doi: 10.3390/jcm11071756. J Clin Med. 2022. PMID: 35407364 Free PMC article.
-
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388. Am J Gastroenterol. 2019. PMID: 31517638 Free PMC article.
-
Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study.Hepatol Int. 2023 Apr;17(2):367-376. doi: 10.1007/s12072-022-10458-w. Epub 2022 Dec 21. Hepatol Int. 2023. PMID: 36542262
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical